Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled Trial

The optimal duration of antiplatelet therapy (APT) in patients at high bleeding risk with or without oral anticoagulation (OAC) after coronary stenting remains unclear. METHODS: In the investigator-initiated, randomize, open-label MASTER DAPT trial (Management of High Bleeding Risk Patients Post Bio...

Descripción completa

Detalles Bibliográficos
Autores principales: Smits, Pieter C., Frigoli, Enrico, Tijssen, Jan, Jüni, Peter, Vranckx, Pascal, Ozaki, Yukio, Morice, Marie-Claude, Chevalier, Bernard, Onuma, Yoshinobu, Windecker, Stephan, Tonino, Pim A.L., Roffi, Marco, Lesiak, Maciej, Mahfoud, Felix, Bartunek, Jozef, Hildick-Smith, David, Colombo, Antonio, Stankovic, Goran, Iñiguez, Andrés, Schultz, Carl, Kornowski, Ran, Ong, Paul J.L., Alasnag, Mirvat, Rodriguez, Alfredo E., Moschovitis, Aris, Laanmets, Peep, Heg, Dik, Valgimigli, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500374/
https://www.ncbi.nlm.nih.gov/pubmed/34455849
http://dx.doi.org/10.1161/CIRCULATIONAHA.121.056680

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500374/
https://www.ncbi.nlm.nih.gov/pubmed/34455849
http://dx.doi.org/10.1161/CIRCULATIONAHA.121.056680

Ejemplares similares